Mammalian cells contain several chromatin-remodeling complexes associated with the Brm and Brg1 helicaselike proteins. These complexes likely represent the functional homologs of the SWI/SNF and RSC complexes found in Saccharomyces cerevisiae. The mammalian chromatin-remodeling complexes are involved in both activation and repression of a variety of genes. Several lines of evidence also indicate that they play a speci®c role in the regulation of cell growth. Brm is down-regulated by ras signaling and its forced reexpression suppresses transformation by this oncogene. Besides, the Brg1 gene is silenced or mutated in several tumors cell lines and a Brg1-associated complex was recently found to co-purify with BRCA1, involved in breast and ovarian cancers. Finally, the gene encoding SNF5/Ini1, a subunit common to all mammalian SWI/ SNF complexes, is inactivated in rhabdoid sarcomas, a very aggressive form of pediatric cancer. The current review will address observations made upon inactivation of Brm, Brg1 and SNF5/Ini1 by homologous recombination in the mouse, as well as the possible implication of these factors in the regulation of the Retinoblastoma pRb-mediated repression of the transcription factor E2F. Oncogene (2001) 20, 3067 ± 3075.
Introduction
Within the nucleus of an eucaryotic cell, DNA is wrapped around the histone octamers composed of two copies of each of the histones H2A, H2B, H3 and H4. These histone-DNA complexes known as the nucleosomes form a potent obstacle for biological processes requiring access to the DNA, like transcription, replication or DNA repair. The cellular machineries allowing transcription factors to gain access to their target promoters have been extensively studied in the last decade. These machineries can be divided in two categories: the histone acetylases and the chromatin remodeling complexes. The histone acetylases or HATs add acetyl groups to the N-terminal tails of the histones that protrude out of the nucleosome core particle. The exact eect of this modi®cation is still unclear but it is likely that the loss of positive charges modify interactions between the histone tails and the DNA or the neighboring nucleosomes. The reaction can be reversed by histone deacetylases (HDACs) that have a negative eect on transcriptional activity. The second category of factors that aect chromatin encompasses protein complexes that use the energy of ATP-hydrolysis to weaken the interaction between histone core particles and DNA. These complexes facilitate the binding of transcription factors to speci®c DNA sites and may thus mediate both activation and repression, depending on the activity of the recruited transcriptional regulator.
SWI/SNF complexes in Saccharomyces cerevisiae
The prototype of the chromatin-remodeling complexes is the SWI/SNF complex. This complex of 11 subunits was initially characterized in S. cerevisiae through genetic and biochemical studies. Its chromatin-remodeling activity relies on the SWI2/SNF2 subunit that contains a large helicase-like domain functioning as a DNA-dependent ATPase. Mutations in any of the swi/ snf genes give rise to various phenotypes, including poor growth, the inability to use speci®c carbon sources and defects in mating type switching. However, these genes are not required for viability. Whole genome expression analysis has shown that the SWI/ SNF complex is required for normal expression of only 3 to 6% of all the S. cerevisiae genes, depending on the study (Holstege et al., 1998; Sudarsanam et al., 2000) . About half of the genes aected more then threefold in swi/snf mutant strains are upregulated rather than downregulated, indicating that the SWI/SNF complex is also involved in transcriptional repression. It must also be noted that the genes regulated by SWI/SNF are scattered all over the genome, suggesting that the complex aects chromatin structure locally rather than remodeling larger chromosomal domains (Sudarsanam et al., 2000) .
S. cerevisiae expresses several other helicase-like proteins related to the catalytic subunit of the SWI/ SNF complex. Among these proteins, Sth1p has the highest degree of homology with SWI2/SNF2 and it is associated with a large complex containing at least four other proteins homologous to SWI/SNF subunits (Table 1 ). In addition, this complex, known as RSC (for Remodel the Structure of Chromatin) contains two actin-related subunits (Arp7p and Arp9p) also present in the SWI/SNF complex. Several dierences exist however between the RSC and the SWI/SNF complex. RSC is essential for growth and about 10-fold more abundant than the SWI/SNF complex. RSC function is required for normal cell cycle progression (Cao et al., 1997; Du et al., 1998; Laurent et al., 1992) but the involvement of the RSC complex in RNA Polymerase II transcription has been somewhat controversial. Unlike most SWI/SNF proteins, RSC subunits do not activate transcription when tethered to DNA through a heterologous DNA-binding domain (Sigrid Schaper and Moshe Yaniv, unpublished observation) . Besides, at non-permissive temperatures, a ts mutation in Sth1 induces alterations of centromeric chromatin structure and perturbs chromosome segregation (Tsuchiya et al., 1998) . Other observations do however connect the RSC complex with transcription. Some rsc mutations aect the expression of the CHA1 gene as well as certain genes involved in early meiosis (Moreira and Holmberg, 1999; Yukawa et al., 1999) . The RSC complex also appears to cooperate with histone acetylases. Indeed, the rsc1 and rsc2 genes code for similar proteins and only mutation of both genes is lethal. However a rsc1 or a rsc2 mutation, in combination with mutations that impair the SAGA histone acetylase complex, either cause lethality or strong mutant phenotypes. This clearly suggests a role for the RSC complex in transcription regulation through chromatin remodeling (Cairns et al., 1999) .
SWI/SNF complexes in higher eucaryotes
SWI/SNF proteins have been identi®ed in several species other than yeast, including Arabidopsis, Drosophila, C. elegans, Xenopus, chick, mouse and human. In Drosophila, the closest relative of SWI2/SNF2 is Brahma. It was initially isolated in a screen for dominant suppressors of Polycomb mutations (Tamkun et al., 1992) . Subsequent biochemical studies showed that the protein is associated with a complex very similar to the yeast SWI/SNF complex, containing at least six subunits related to SWI/SNF subunits (Dingwall et al., 1995; Papoulas et al., 1998) . Another SWI2/SNF2-related protein, known as ISWI, has been found associated with dierent chromatin remodeling complexes (Ito et al., 1997; Tsukiyama and Wu, 1995; Varga-Weisz et al., 1995) . However, it is clear that only the Brahma-associated (or BAP) complex has a composition and an activity closely related to yeast SWI/SNF (Kal et al., 2000) .
In mammalian cells, the situation is far more complicated. These cells contain at least two proteins closely related to SWI2/SNF2, known as Brm and Brg1 (or SNF2a and SNF2b, respectively) . In addition, biochemical studies have identi®ed dierent variants of the mammalian SWI/SNF complex that all contain subunits related to several yeast SWI/SNF proteins ( Table 1 ). The SWI/SNF complexes elute in two distinct fractions during puri®cation. The ®rst fraction contains two dierent complexes associated with either Brm or Brg1, respectively. Because of their similar biochemical properties, they are both referred to as the BAF or the SWI/SNF-A complex. They are characterized by the presence of BAF250, a low speci®city DNA-binding subunit with homology to yeast SWI1 and Drosophila OSA. A subfraction of the BAF complexes apparently also contains the tumor suppressor protein BRCA1 (Bochar et al., 2000) . The second chromatographic fraction contains a complex called PBAF or SWI/SNF-B. This complex is apparently associated only with Brg1 and not Brm. It also contains the Polybromo protein that is not present in the BAF complex. Polybromo, also called BAF180, contains six successive Bromodomains and shares some homology with three subunits of the yeast RSC complex, Rsc1, Rsc2 and Rsc4, both within and (Chiba et al., 1994; Khavari et al., 1993; Muchardt and Yaniv, 1993) (Kalpana et al., 1994; Muchardt et al., 1995) , 11 (Kal et al., 2000) , 12 , 13 (Zhao et al., 1998) , 14 (Cairns et al., 1999) , 15 ¯anking the Bromodomains (Cairns et al., 1999; Callebaut et al., 1999) . The presence of Polybromo in the PBAF complex suggests that PBAF may in fact correspond to the yeast RSC complex. On the other hand, only the bona ®de yeast SWI/SNF complex contains a SWI1 subunit. Therefore, the BAF250-associated BAP complex may be the true mammalian SWI/SNF complex Xue et al., 2000) . Recently, subunits of the BAF/PBAF complexes have been found in a fourth complex named N-CoR, for Nuclear Receptor CoRepressor'. Within this complex, Brg1, Baf170, Baf155 and SNF5/INI1 are associated with the histone deacetylase HDAC3 and the corepressor Kap1/TIF1b (Underhill et al., 2000) . In lymphoid cells, SWI/SNF subunits are also associated with the transcriptional regulator Ikaros required for normal B and T cell dierentiation (Kim et al., 1999; O'Neill et al., 2000) . Similarly, erythroid cells contain a SWI/SNF-like complex associated with EKLF, a key regulator of b-globin gene expression (Armstrong et al., 1998; Kadam et al., 2000) . This wealth of SWI/ SNF complexes suggests that in mammals, some SWI/ SNF sub-complexes are dedicated to either activation or repression of speci®c pathways, possibly with a restricted tissue-distribution.
Inactivation of Brm and Brg1 in mammalian cells
Early studies have shown that two human cell lines, C33A and SW13, contain either very low or undetectable levels of both Brm and Brg1 (Muchardt and Yaniv, 1993) . Systematic screening has further identi®ed at least half a dozen human tumor cell lines carrying truncating mutations in the Brg1 gene on both alleles (Wong et al., 2000) . All of these lines have lost Brg1 expression entirely and in most cases, Brm is either present at reduced levels or absent ( Table 2 ). The Brg1 gene can also be inactivated in primary mouse embryo ®broblasts without aecting cell viability (Bultman et al., 2000) . In mouse embryonic ES and F9 cells, the Brm protein is low or absent and its expression is only induced upon dierentiation. Finally, many murine cell lines lose Brm expression upon transformation (LeGouy et al., 1998; Muchardt et al., 1998) . From these observations, it appears clearly that expression of Brm is cell-type and transformation-dependent and that neither Brm nor Brg1 are required at all times. The existence of cell lines apparently missing both Brm and Brg1 further suggests that in speci®c cases, SWI/ SNF activity is dispensable in mammalian cells. This may however not be a general rule. Inactivation of one allele of the Brg1 gene by homologous recombination in F9 cells severely aects proliferation, and a homozygous deletion of the gene in these cells is lethal (Sumi-Ichinose et al., 1997) . We have also noted that the human ovary carcinoma cell line OV-1063 that does not express Brg1, contains levels of Brm 2 ± 3-fold higher than average, suggesting that in some cases, loss of Brg1 must be compensated by up-regulation of the Brm gene (CM, unpublished observation).
Inactivation of the mouse Brm gene by homologous recombination has con®rmed that it is dispensable for viability. Brm nullizygous mice are born at normal mendelian ratios. They are viable and fertile. Several observations suggest, however, a moderate deregulation in the control of cell growth. First, mutant animals exhibit a 10 to 15% increase in body mass, relative to their wild-type littermates. Increased cell proliferation was also observed in the liver, and embryonic ®broblasts isolated from the mutant animals failed to show proper growth arrest at con¯uency . Interestingly, the Brm knockout mice showed a 2 ± 6-fold increase in the expression of Brg1 in several tissues. It is likely that this upregulated Brg1 expression compensates for the lack of Brm.
Inactivation of the Brg1 gene is lethal at a very early stage and embryos die before implantation. Explanted blastocytes carrying the Brg1 null mutation fail to hatch from their zona pellucidae and no cellular proliferation is observed. Heterozygote Brg1 mutants are under-represented at birth and about 15 to 30% of these mutants show signs of exencephaly in utero. After birth, heterozygotes are viable and fertile but around 16 months of age, a fraction of these mice display large subcutaneous tumors localized to the neck or ingineal regions (Bultman et al., 2000) . The tumors appearing in the Brg1 heterozygous mice have apparently not lost the second Brg1 allele. Taken together with the exencephaly observed on the heterozygous embryos, this suggests that the dosage of the Brg1 protein is important for proper function.
Given the high degree of homology between Brg1 and Brm (86% similar and 75% identical), the very dierent phenotypes of the respective null mutants are rather surprising. As mentioned above, the PBAF version of the mammalian SWI/SNF complex may only contain Brg1 whereas the BAF complex can contain either Brg1 or Brm. If this observation is correct, the PBAF complex is inactivated in Brg1 null mutants whereas the BAF complex will still be able to form with Brm. It has therefore been suggested that the PBAF complex is more important for cell viability than the BAF complex and that the absence of this PBAF complex could be responsible for the early lethality induced by Brg1 inactivation . This situation would mimic the situation in S. cerevisiae where the RSC complex is required for viability whereas the SWI/SNF complex is dispensable. Alternatively, Brg1 and Brm may potentially be able to compensate for each other, but may in some cases be prevented from doing so because of restricted expression in time and in space. In fact, it was shown that levels of Brm increase gradually during mouse development to reach a maximum in adult post-mitotic tissues. Brg1, on the other hand, is apparently present at similar levels throughout development (LeGouy et al., 1998; Reyes et al., 1998) . Likewise, in tissue culture mouse ®broblasts, Brg1 protein levels appear stable through the cell cycle, whereas Brm is only present at Oncogene Mammalian SWI/SNF and the cell cycle C Muchardt and M Yaniv high levels in growth arrested cells . It is therefore possible that Brg1 plays the principal role in SWI/SNF activity during development and cannot be replaced by Brm because of its insucient expression. Studies of the early mouse embryo also suggest that timing of the Brg1 and Brm expression could explain the early lethality induced by the Brg1 null mutation. Indeed, the oocyte contains both Brg1 and Brm of maternal origin. However, at the 4-cell stage, when zygotic transcription starts, the Brg1 gene is clearly expressed whereas Brm mRNA is almost undetectable. Some Brm mRNA is detected at the 8-cell stage but abundant transcription only starts at the blastocyst stage (Bultman et al., 2000; LeGouy et al., 1998) . It therefore appears that the Brg1 nullizygote mice go through a short window of time when they are missing both Brg1 and Brm. The absence of a functional SWI/SNF complex at the onset of zygotic transcription may lead to defective reprogramming of the embryonic chromatin, ultimately leading to death before implantation.
Inactivation of the SNF5/INI1 gene
One subunit of the mammalian SWI/SNF complexes has been clearly demonstrated to function as a tumor suppressor. This protein known as SNF5/INI1 or BAF47 is a homolog of S. cerevisiae SNF5 (Kalpana et al., 1994; Muchardt et al., 1995; Wang et al., 1996) . It is present in all versions of the mammalian SWI/ SNF complex puri®ed to date but has also been shown to be involved in HIV integration (Kalpana et al., 1994; Morozov et al., 1998; Parissi et al., 2000) . Recently, biallelic mutations in the SNF5/INI1 gene were shown to be the causative event leading to malignant rhabdoid sarcomas, a very aggressive form of pediatric cancer (Versteege et al., 1998 No homozygous mutants are detected at 6.5 days p.c and explanted blastocysts either fail to hatch from their zona pellucida or do not proliferate properly after hatching. These observations suggest that like Brg1 null mutants, SNF5/INI1 nullizygotes die at a peri-implantation stage. Heterozygous SNF5/INI1 mutants show, like in human, increased susceptibility to an early onset of cancer. In our study, 32% of the heterozygous animals developed tumors by the age of 15 months. These tumors were detected at dierent locations but were most frequent in the nervous system and in soft tissues (Klochendler-Yeivin et al., 2000) .
Many of these observations were con®rmed by a second study (Roberts et al., 2000) . In this case, it was noted that a majority of the tumors were found in structures derived from the ®rst bronchial arch. In the two studies, a large fraction of the tumors showed similarities with human rhabdoid sarcomas although the onset of the tumorigenesis was clearly delayed in mice compared to human. Besides, in humans, thè rhabdoid predisposition syndrome' caused by constitutional SNF5/INI1 mutations has a very high penetrance (SeÂ venet et al., 1999b) , whereas only onethird of the heterozygous mice develop tumors. The molecular events causing these dierences are still unknown.
Why does the SWI/SNF complex aect cell growth? The pRb connection As described above, many observations made in both cell lines and knockout animals suggest that the mammalian SWI/SNF complex is linked to the control of cell proliferation. As we will see, there are several possible explanations for this connection, most likely re¯ecting the large number of genes transcriptionally regulated by the SWI/SNF complex. The best documented link between members of the SWI/SNF complex and regulators of the cell cycle, concerns the interaction between Brm or Brg1 and the Retinoblastoma protein pRb. This interaction was initially discovered in yeast two-hybrid screen using pRb as a bait (Dunaief et al., 1994) . Association of pRb with Brm has also been described, as well as interaction of other Rb family members with both Brm and Brg1 (Fryer and Archer, 1998; Singh et al., 1995; Strober et al., 1996; Trouche et al., 1997) . The fragment of Brg1 encoded by the partial cDNA isolated in the initial two-hybrid screen, contained an LXCXE motif. This motif is known to mediate interaction of the`pocket' domain of pRb with Adenovirus E1a, SV40 large T and Papilloma E7 as well as several cellular proteins, such as the histone deacetylases HDAC1 and HDAC2. However, later studies using Brg1 derivatives carrying point mutations in the LXCXE motif have shown the integrity of this motif to be dispensable for interaction with Brm or Brg1 Zhang et al., 2000) . Regions neighboring the LXCXE motif also show homology to Adenovirus E1a and may be the real site of pRb interaction (Trouche et al., 1997) .
The pRb protein is one of the major cell cycle regulators that controls the G1/S transition as well as progression through S phase. In early G1, when the protein is hypophosphorylated, it associates with the transcription factor E2F and recruits histone deacetylases. These events cause the repression of several E2F-dependent genes involved in cell cycle progression, like Cyclin A and Cyclin E. In late G1, accumulation of Cyclin D/Cdk4/6 complexes results in phosphorylation of the pRb pocket. These phosphorylation events lead to the displacement of the HDAC activities and ultimately to the release and the activation of E2F Oncogene Mammalian SWI/SNF and the cell cycle C Muchardt and M Yaniv (Harbour et al., 1999) . Several functional assays have demonstrated an implication of Brg1 and Brm in the control exerted by pRb on the G1/S transition. Transfection experiments have shown a cooperation between Brm and pRb in the repression of E2F-dependent transcriptional activation (Trouche et al., 1997) . Furthermore, several studies have shown a cooperation between pRb and Brm or Brg1 for induction of growth arrest. In SW13 cells that express neither Brm nor Brg1, but contain a wild type pRb, overexpression of either of the two SWI/SNF proteins leads to the formation of¯at growth arrested cells. This eect is inhibited by co-transfection of Adenovirus E1a (Dunaief et al., 1994; Strober et al., 1996) . Cell lines lacking Brm and Brg1 are also resistant to growth arrest induced by a constitutively active pRb that cannot be phosphorylated. This resistance can be overcome by re-introducing Brg1 into the cells (Strobeck et al., 2000a,b) . One study based on pRb overexpression in tumor cell lines also suggests that the mammalian SWI/SNF complex is necessary for the orderly expression of Cyclin E and Cyclin A during late G1 and S (Zhang et al., 2000) . As mentioned above, HDACs interact with the pRb pocket via their LXCXE motif whereas Brg1 apparently associates with the Retinoblastoma protein through a neighboring domain. The formation of a ternary complex containing HDAC, pRb and Brg1 is therefore possible. According to Zhang et al. (2000) , this complex represses both the Cyclin E and the Cyclin A promoters. Phosphorylation of the pocket region of pRb in late G1 by Cyclin D/Cdk4 seemingly displaces HDAC from the ternary complex without aecting the Brg1-pRb interaction. The resulting binary complex still represses the Cyclin A, but not the Cyclin E promoter. This residual complex is only disrupted in S phase upon accumulation of CyclinE/Cdk2. These observation are compatible with the ®nding that cells growth-arrested by Brg1 and pRb accumulate in S phase and not in G1. Interestingly, Brg1-pRb-induced repression of the Cyclin A promoter was relieved by Cyclin E/Cdk2 even when wild type pRb was replaced by a mutant RbDcdk, which cannot be inactivated Cdk phosphorylation. This suggests that pRb phosphorylation by Cyclin E/Cdk2 is not the causative event leading to activation of the Cyclin A promoter. An earlier study has shown that Brg1 associates with Cyclin E and can be inactivated by Cyclin E/Cdk2 phosphorylation (Shanahan et al., 1999) . Furthermore, in Drosophila, reduced Cyclin E function in the eye imaginal disk leads to disruption of the regular patterning of the eye, due to defective S phase entry of cells posterior to the morphogenetic furrow (de Nooij and Hariharan, 1995) . Mutations in the Drosophila Brahma gene can compensate for this rough eye' phenotype, demonstrating a genetic link between the SWI/SNF complex and Cyclin E (H Richardson, personal communication). It is therefore possible that Brg1 phosphorylation by Cyclin E/Cdk2 is a major event leading to progression through S phase.
What is the function of the SWI/SNF complex when associated with pRb and E2F?
Like down-regulation of Drosophila Cyclin E, overexpression of dE2F and the associated dDP disrupt the patterning of the Drosophila eye. In¯ies overexpressing these two proteins, the`rough eye' phenotype can be compensated by overexpression of the Drosophila pRb homolog RBF. Interestingly, the phenotype can also be enhanced by`loss of function' mutations in three genes encoding members of the Drosophila SWI/SNF complex, namely Brahma, Moira and Osa (Staehling-Hampton et al., 1999) . This observation indicates that the SWI/SNF complex is required for E2F activation and not just for regulation of pRb mediated repression. It is therefore possible that in early G1, the SWI/SNF complex facilitates the binding of E2F to its target promoters by increasing their accessibility. The simultaneous recruitment of pRb and the associated histone deacetylase activities may then prevent the binding of other transcription factors to the promoters. It has been demonstrated in vitro that the SWI/SNF complex can catalyze the opening of the nucleosome structure but also the reverse reaction (Schnitzler et al., 1998) . It is therefore possible that after facilitating the recruitment of E2F, the SWI/SNF complex also plays an active role in preventing this transcription factor from mediating activation. What determines the activating or the repressing eect of the SWI/SNF complex remains unclear, but the eect of the complex seems to be dependent on the presence of the histone tails and on their state of acetylation Logie et al., 1999; Syntichaki et al., 2000) . Furthermore, both Brg1 and Brm contain a Bromodomain. This conserved motif is known from other proteins to mediate interaction with acetylated histones (Dhalluin et al., 1999; Hudson et al., 2000; Jacobson et al., 2000; Owen et al., 2000) . Thus, the equilibrium between histone acetylating and deacetylating activities may be the main determinant of E2F-induced promoter activation and this may be what pRb is in fact regulating. In parallel, it must be noted that embryonic ®broblasts isolated from Brm7/7 mice fail to up-regulate p27kip1 at con¯uency. p27kip1 is a member of the p21 family that inhibits Cyclin D/Cdk4, Cyclin E/Cdk2 and Cyclin A/Cdk2. Brm and Brg1 expression may therefore cause downregulation of the kinases inactivating pRb and thereby provide indirect stimulation of pRb-mediated repression .
The respective roles of Brm and Brg1 in pRb mediated growth arrest is still debated. It is clear that both proteins can cooperate with pRb upon overexpression (Strober et al., 1996) . However, in tissue culture cells, the level of Brm expression is low during exponential growth. For example in NIH3T3 cells, Brm accumulates in G0 but becomes almost undetectable after stimulation of the cells with serum. On the other hand, Brg1 is abundant throughout the cell cycle . Under physiological condi-tions, it is therefore likely that in late G1 and S phase, the major catalytic subunit of the mammalian SWI/ SNF complex is Brg1 and not Brm. Nevertheless, Brm may also play an important role in the control of cell cycle. First, as mentioned above, Brm expression is induced upon dierentiation of F9 and ES cells. Second, it is frequently down-regulated or absent in transformed mouse cells. Re-introduction of Brm in ras-transformed mouse ®broblasts leads to reversion of the transformed phenotype . In this same assay, Brg1 showed little eect, possibly because ectopic expression of Brg1 leads to downregulation of the endogenous Brg1 gene, keeping the total levels of Brg1 protein essentially constant (B Bourachot and C Muchardt, unpublished observation). It is therefore likely that Brm and Brg1 have the same potential eect on the cell cycle but that they are regulated in very dierent ways. Brg1 may be the important protein during interphase where it is present in well de®ned amounts and regulated by phosphorylation. On the other hand, Brm appears to be an inducible protein that may allow to increase the total amount of active SWI/SNF complex present in the cells. Augmented levels of SWI/SNF complex may permit regulation of targets speci®c for growth arrest and dierentiation.
The BRCA1 connection
As mentioned above, the BRCA1 tumor suppressor protein has also been found associated with what appears to be a version of the BAF mammalian SWI/ SNF complex (Bochar et al., 2000) . The BRCA1 gene is mutated in 50% of inherited breast cancers and 90% of all familial breast and ovarian cancers. The BRCA1 protein is involved in DNA damage repair and its inactivation leads to genetic instability (see Deng and Scott, 2000, for review) . However, the protein has also been directly implicated in transcriptional activation. It was found associated with RNA polymerase II and the co-activators CBP and p300. BRCA1 was also shown to function as a co-activator of p53-mediated transcription (see Monteiro, 2000, for review) . The p53 protein is responsible for G1 and G2 arrest upon DNA damage. It is a transcription factor that upon induction up-regulates expression of the p21WAF1 Cdk-inhibitor and thereby prevent the inactivating phosphorylation of pRb (see Vousden, 2000, for review) . The eect of BRCA1 on p53-mediated transcription is inhibited by a transdominant Brg1 mutated in its ATP-binding site (Bochar et al., 2000) . This observation raises the possibility that the mammalian SWI/SNF complex also controls cell cycle through the p53 pathway. It must however be noted that overexpression of BRCA1 can lead to growth arrest in a Rb-dependent manner and that an interaction between BRCA1 and pRb has been described (Aprelikova et al., 1999) . It is therefore possible that BRCA1 is in fact part of the Brg1-pRb cell-cycle control pathway described above.
What about SNF5/INI1?
Although SNF5/INI1 is the only con®rmed tumor suppressor protein present in the SWI/SNF complex, connections linking this protein to the cell cycle can only be inferred. The SNF5/INI1 protein is present in all mammalian SWI/SNF complex puri®ed to date and it is possible that, unlike Brm and Brg1 that are at least partially redundant, inactivation of the SNF5/INI1 subunit leads to overall inactivation of SWI/SNF activity. If a complete SWI/SNF complex is required for pRb mediated repression, inactivation of SNF5/ INI1 may jeopardize this growth control pathway and lead to cancer. It must however be noted that mouse Rb 7/7 embryos die much later SNF5/INI1 null mutants (Jacks et al., 1992; Klochendler-Yeivin et al., 2000) . Furthermore, the spectrum of tumors is dierent in Rb and SNF5/INI1 heterozygous mice. This is also true in human patients. It is possible that SNF5/INI1 cooperates with other Rb family members and that inactivation of this gene leads to complete disruption of Rb function. However, SNF5/INI1 may also aect the cell cycle through other pathways. The protein has been found to interact with the product of the HRX gene, frequently disrupted in human acute leukemia (Alder et al., 1999) and interaction between SNF5/INI1 and E1 stimulates replication of the papillomavirus DNA (Lee et al., 1999) . Finally, SNF5/INI1 interacts directly with the proto-oncogene c-MYC. This protein is a transcription factor that plays a key role in cell proliferation, dierentiation and apoptosis (see Grandori et al., 2000, for review) . When dimerized with MAX, c-MYC binds DNA and activates transcription. This activation is at least in part due to the recruitment of the TRRAP-GCN5 histone acetylase complex (McMahon et al., 2000) . Activation apparently also requires the presence of SNF5/INI1 and possibly the entire SWI/SNF complex (Cheng et al., 1999; Takayama et al., 2000) . This observation suggests that loss of an intact SNF5/INI1 protein will cause down-regulation of c-MYC activation. It is unclear how this event could lead to cell transformation but it has been suggested that SNF5/INI1 may primarily participate in c-MYC-mediated activation of genes involved in apoptosis (Cheng et al., 1999) .
Pespectives
Many questions remain open on the way mammalian SWI/SNF subunits may regulate the cell cycle. For example, although many groups have now demonstrated an interaction between pRb and Brg1 or Brm, pRb was never found to co-elute with the puri®ed SWI/SNF complex (Wang et al., 1996) . It can therefore not be ruled out that pRb repression is mediated by a speci®c SWI/SNF sub-complex, which has yet to be identi®ed. It is even possible that Brg1 or Brm alone are the only subunits required for this process. Similarly, the striking dierences between pRb and SNF5/INI1 knockout mice clearly tells that we still Oncogene Mammalian SWI/SNF and the cell cycle C Muchardt and M Yaniv have a poor understanding on how SNF5/INI1 mutations can lead to tumorigenesis. Again, it can not be ruled out that this protein has a function beyond the mammalian SWI/SNF complexes as they are known today. Mouse models allowing conditional inactivation of Brg1 and SNF5/INI1 are on the way. Unlike the simple knockouts, these mice should give us some insights on the eect of the SWI/SNF proteins at later stages of development and will hopefully provide much needed information on their role in the control of cell growth.
